Maria Bassanelli
A5069428078- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Mass Spectrometry Techniques and Applications
- Ubiquitin and proteasome pathways
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer survivorship and care
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2024
Sapienza University of Rome
2014-2022
Ospedale generale di zona San Camillo Treviso
2017-2021
Ellis Hospital
2018
Azienda Ospedaliera Sant'Andrea
2017
Expert System (Italy)
2016
CTO Andrea Alesini
2014-2015
Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...
The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction immune-based combinations. role cytoreductive nephrectomy (CN) in these patients is still debated. ARON-1 study (NCT05287464) was designed to globally analyze real-world data mRCC receiving first-line immuno-oncology This sub-analysis focused on or delayed partial radical CN three geographical areas (Western Europe, Eastern America/Asia).We conducted a multicenter retrospective...
Background: The combination of radiotherapy (RT) and programmed death 1 inhibitors seems to increase antitumor immune responses. Objective: To assess the outcome role best sequence, i.e. immunotherapy given before, during, and/or after RT, in patients with non-small cell lung cancer (NSCLC). Methods: We conducted an observational, retrospective analysis 95 consecutive advanced NSCLC who received any treatment nivolumab, as clinically indicated. Median overall survival (OS) 95% confidence...
Abiraterone acetate (AA) demonstrated its efficacy in the treatment of patients with metastatic castration resistance prostate cancer (mCRPC) predocetaxel and postdocetaxel setting. However, we learn from pivotal studies that forms primary acquired to this drug exist. Patient selection becomes so crucial optimize results. Potential predictive biomarkers have been identified but are not yet validated. In scenario, clinical features disease characteristics may still be value selecting for...
Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence brain metastases from RCC is less than 20% cases. Traditionally, whole radiotherapy as well the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization clinical symptomatology. However, validated treatment guidelines patients with are not yet available on account frequent exclusion such trials. Moreover, limited data sequential...
The Identification of reliable Biomarkers able to predict the outcome after nephrectomy patients with clear cell renal carcinoma (ccRCC) is an unmet need. gene expression analysis in tumor tissues represents a promising tool for better stratification ccRCC subtypes and patients’ evaluation. Methods: In our study we retrospectively analyzed using Next-Generation (NanoString), panel tissue from 46 consecutive treated non-metastatic at two Italian Oncological Centres. Significant differences...
<b><i>Introduction:</i></b> Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, recently approved in Europe for the first-line treatment metastatic renal cell carcinoma (mRCC). <b><i>Methods:</i></b> Retrospective analysis safety activity tivozanib administered at 1.34 mg daily (3 weeks on, week off) within compassionate-use program to patients with mRCC no...